Lung Injury Clinical Trial
Official title:
Food Intake REstriction for Health OUtcome Support and Education (FIREHOUSE) Trial
NCT number | NCT03581006 |
Other study ID # | 17-00127 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 12, 2018 |
Est. completion date | March 4, 2021 |
Verified date | December 2021 |
Source | NYU Langone Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
This is a randomized-controlled unblinded clinical trial to investigate dietary intervention on metabolic biomarker assessment in World Trade Center (WTC) Lung Injury (LI) in firefighters. The purpose of this study is to evaluate biomarkers of metabolic dysregulation that have previously been found to predict WTC-LI in a case cohort study selected from the entire exposed firefighter cohort, and attempt to alter these metabolites using dietary intervention and a technology-supported behavioral modification program. Investigators will measure Pre/Post global metabolic expression in WTC-exposed, symptomatic firefighter serum sampled after 6-month intervention, as well as clinical outcomes of WTC-LI in the study group vs controls.
Status | Completed |
Enrollment | 100 |
Est. completion date | March 4, 2021 |
Est. primary completion date | March 4, 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 21 Years to 90 Years |
Eligibility | Inclusion Criteria: 1. Age 21-90. 2. Born male sex and currently identify as genetic male 3. FDNY rescue and recovery worker. 4. Documented WTC exposure. 5. Enrolled in the FDNY WTC Health Program 6. Subjects are willing and able to consent for themselves to study enrollment 7. Subjects are willing and able to participate in study procedures 8. Are able to perform their activities of daily living independently 9. Are either light duty or retired FDNY Firefighters 10. Have an FEV1 less than the LLN of predicted for age/sex/weight documented at any time after 9/11/2001. 11. Have a BMI>27 kg/m2 and <50kg/m2 12. Willing and able to modify their diet and activity level. 13. Subjects who have a spirometry available within the last 36 months, and at their post-9/11 visits at the FDNY 14. Demonstrate minimal proficiency using a smart phone 15. Have means to accommodate transportation to/from in-person visits Exclusion Criteria: 1. Have pre-existing and documented conditions or concurrent diagnoses, including (and not necessarily limited to) active cancer, severe heart disease, significant cognitive impairment, eating disorders, significant psychiatric illness, end-stage COPD, severe pulmonary hypertension, or organ transplant. 2. Concomitant use of interfering medication(s) or devices currently or within the month prior to enrollment, including anti-retrovirals, human monoclonal antibodies, supplemental daytime oxygen, and insulin pumps. 3. Severe gastrointestinal issues or illnesses that would prevent adherence to the proposed diets. 4. Severe kidney disease requiring dialysis 5. Severe liver disease requiring frequent medical intervention 6. Participating in other diet modification studies. 7. High dose steroid (>20mg prednisone or equivalent) or other hormonal treatments/chemotherapy use in the last month, including testosterone supplementation. 8. Life-expectancy < 6 months 9. BMI =50 kg/m2 or =27 kg/m2 10. Recent significant intentional or unintentional weight loss, defined as over 5% reduction in total body weight over the last month. (Blackburn Criteria). 11. Significant or severe alcohol abuse disorder |
Country | Name | City | State |
---|---|---|---|
United States | New York University School of Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Body mass index (BMI) | Body mass (weight in kg) divided by square of the body height (measured in meters), expressed in units kg/m^2 | 4 Years | |
Secondary | Pulmonary Function using FEV Measure | Forced expiratory volume (FEV) using spirometer that measures the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. | 4 Years | |
Secondary | St. George's Respiratory Questionnaire (SGRQ) | Airways-disease specific paper questionnaire assessing symptoms, effect on activity level, and impact on quality of life. | 4 Years | |
Secondary | Electrocardiogram (EKG) | Non-invasive brief electrical recording of heart rate and rhythm using electrodes placed on the chest | 4 years | |
Secondary | Fraction of exhaled nitrous oxide (FENO) | Simple breathing test to measure airway inflammation as often seen in asthma or particulate matter lung injury, measured in ppb. | 4 years | |
Secondary | Pulse Wave Velocity (PWV) | Non-invasive measurement to ascertain vascular stiffness, by measuring the velocity at which the blood pressure pulse propogates through the circulatory system. This is done using a simple non-invasive blood pressure cuff assessment at the carotid and femoral arteries. It is measured as a velocity, in meters/per second. | 4 years | |
Secondary | Individual microbiome profile - stool sample | Simple home collection of a stool sample using a sterile collection kit, provided to the human subject. Stool will be used to generate a microbiome profile unique to that individual, reported as bacterial species found in the gut flora, that may predict lung injury. There is no risk to the human subject aside that of providing a stool sample. All individual information is de-identified for personal protection. | 4 years | |
Secondary | 6-minute walk test (6MWT) | Simple exercise capacity assessment measuring distance walked over 6 minutes, measured in meters. | 4 years | |
Secondary | Individual metabolomic profile - blood sample | Routine blood testing via sterile phlebotomy to assess metabolic biomarkers that may or may not predict lung injury. These metabolites are generated in all individuals based on their dietary and exercise habits, underlying comorbidities, and unique metabolism. Measured in routine blood samples, and quantified based on unique chemical composition of that molecule. There is no additional risk to the human subject aside that of venipuncture. | 4 years | |
Secondary | Individual genomic profile - saliva sample | Simple home collection of sputum/saliva sample using a buccal swab kit, provided to the human subject. Saliva will be used to generate a genetic profile unique to that individual, reported as chromosomes, genes, and proteins that may predict lung injury. There is no risk to the human subject aside that of providing a sputum sample. All individual information is de-identified for personal protection. | 4 years | |
Secondary | Short-form-36 (SF-36) questionnaire | Generalized paper questionnaire for self-assessment of mental health, general health perception, and overall quality of life | 4 years | |
Secondary | Routine vital signs - Heart Rate | Brief assessment of heart rate (pulse) measured in beats/per minute | 4 years | |
Secondary | Routine vital signs - Blood Pressure | Subjects who have spirometry available within the last 36 months, and at their post-9/11 visits at the FDNY. | 4 years | |
Secondary | Routine vital signs - Body temperature | Brief assessment of body temperature using a basic thermometer under the tongue, measured in degrees Fahrenheit | 4 years | |
Secondary | Neck circumference | Assessment of neck circumference using basic measuring tape, recorded in centimeters | 4 years | |
Secondary | Waist circumference | Assessment of waist circumference using basic measuring tape, recorded in centimeters | 4 years | |
Secondary | Bioelectrical impedance analysis (BIA) | Assessment of lean body mass and total body fat percentage using an InBody bioelectrical impedance analysis scale. | 4 years | |
Secondary | Food Frequency Questionnaire | Paper assessment of typical dietary intake over previous one month, multiple choice answers | 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05054270 -
Efficacy of Lung Ultrasound in Monitoring Fluid Resuscitation in Chest Trauma Patients
|
||
Not yet recruiting |
NCT04470297 -
Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT01184313 -
Acute Lung Injury After Aortic Valve Surgery
|
N/A | |
Not yet recruiting |
NCT06446544 -
Functional Residual Capacity and Alveolar Recruitment in Single-lung Ventilation: a Randomized Study
|
N/A | |
Not yet recruiting |
NCT06296173 -
Open Lung Protective Extubation Following General Anesthesia
|
N/A | |
Not yet recruiting |
NCT03661502 -
Effect of Variable Volume Ventilation on Lung Compliance
|
N/A | |
Recruiting |
NCT04296071 -
Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)
|
||
Completed |
NCT04645316 -
The Effect of Sevoflurane and Desflurane on Clara Cell Protein on the Lung
|
N/A | |
Recruiting |
NCT02299921 -
Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure
|
||
Recruiting |
NCT05559970 -
Inhalational Sedation and Mechanical Power
|
N/A | |
Recruiting |
NCT05228717 -
Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19
|
||
Recruiting |
NCT04372953 -
Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial).
|
N/A | |
Not yet recruiting |
NCT05363085 -
The Cerebral-Respiratory Interaction in Controlled Mechanically Ventilated Neurosurgical Patients. (The CeRes-CMV Study)
|
||
Recruiting |
NCT02444858 -
Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Paraquat Poisoning Induced Lung Injury
|
Phase 1/Phase 2 | |
Completed |
NCT03924206 -
Hazardous Surgical Smoke: Risk Assessment and Evaluation of a New Smoke Extractor System in the Surgical Unit
|
||
Recruiting |
NCT06416709 -
Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01939067 -
Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP
|
Phase 1 | |
Recruiting |
NCT05401474 -
Individualization Flow in Patients Treated With High Flow Nasal Therapy (iFLOW)
|
N/A | |
Completed |
NCT03437499 -
Adrenomedullin Changes After Sustained Inflation or Positive Pressure Ventilation at Birth
|
N/A | |
Not yet recruiting |
NCT05381415 -
Effect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD
|